The litigation centers on claims that ADMA Biologics violated the Securities Exchange Act of 1934. The complaint alleges the company engaged in undisclosed related-party transactions and utilized channel stuffing to artificially inflate revenue figures. These actions reportedly created a distorted view of the company’s financial health, leading to investor losses once the underlying realities surfaced.
Legal counsel Brian Schall is currently coordinating with potential class members ahead of the August 10, 2026, deadline. While the class has not yet received formal certification, shareholders who suffered financial damages are invited to review their options for recovery. Those who choose not to participate may remain as absent members, though legal representation remains unavailable until the court certifies the class.
Comments (0)
No comments yet. Be the first!